UroGen Pharma Ltd.
URGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001668243
Insider trades, last 90 days
0 buys · 4 sells
- Sold $3.36M
- Open-market purchases (P) and sales (S), counted by Form 4 filing.
13F holders, Q2 2026
190
- +17 vs. Q1 2026
- Total value $1.56B
Superinvestors holding URGN
1
- At the end of Q2 2026
Price chart
Latest insider trades
View all: Latest insider tradesOpen-market purchases and sales by URGN insiders, newest first.
| Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Sep 9, 20262:37 PM ET | Sep 8, 2026 | Schoenberg MarkChief Medical Officer | SSaleOrdinary Shares | −871 | $42.92 | −$37.38K | 59.88K | −1.4% | SEC |
| Sep 9, 20262:35 PM ET | Sep 8, 2026 | Smith Jason DrewGeneral Counsel | SSaleOrdinary Shares | −1.52K | $42.54 | −$64.62K | 53.14K | −2.8% | SEC |
| Aug 24, 20265:03 PM ET | Aug 20, 2026 | Schoenberg MarkChief Medical Officer | SSaleordinary shares | −60.68K | $47.05 | −$2.85M | 59.09K | −50.7% | SEC |
| Jul 10, 20262:17 PM ET | Jul 9, 2026 | Schoenberg MarkChief Medical Officer | SSaleOrdinary Shares | −10K | $40.00 | −$400K | 119.76K | −7.7% | SEC10b5-1 |
| Jun 24, 2026 | Jun 22, 2026 | Schoenberg MarkChief Medical Officer | SSaleOrdinary Shares | −10K | $35.01 | −$350.1K | 129.76K | −7.2% | SEC10b5-1 |
Top 5 13F holders, Q2 2026
View all: Top 5 13F holders, Q2 2026The largest institutional positions in URGN at the end of Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 4,543,895 | $167.22M | 1.43% | 00.0% | Unchanged |
| BlackRock, Inc. | 3,201,461 | $117.81M | 0.00% | +355,894+12.5% | Added |
| MORGAN STANLEY | 2,576,363 | $94.81M | 0.01% | +16,325+0.6% | Added |
| Kynam Capital Management, LP | 2,434,207 | $89.58M | 4.95% | +186,814+8.3% | Added |
| JEFFERIES FINANCIAL GROUP INC. | 2,199,652 | $80.95M | 0.74% | 00.0% | Unchanged |